Applied Therapeutics, Inc. (APLT) financial statements (2022 and earlier)

Company profile

Business Address 545 5TH AVENUE, SUITE 1400
NEW YORK, NY 10017
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:80,80096,82938,854
Cash and cash equivalents53,88857,46618,850
Short-term investments26,93539,36320,004
Other undisclosed cash, cash equivalents, and short-term investments(23)  
Receivables235 
Prepaid expense2221991,338
Other current assets47128091
Other undisclosed current assets6,8785,2805,872
Total current assets:88,394102,59346,155
Noncurrent Assets
Operating lease, right-of-use asset1,2981,7122,035
Other undisclosed noncurrent assets200201199
Total noncurrent assets:1,4981,9132,234
TOTAL ASSETS:89,892104,50648,389
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities13,4484,3289,138
Accounts payable9,4616408,793
Accrued liabilities1,2081,585345
Employee-related liabilities2,7792,103 
Debt  356
Other liabilities987553264
Other undisclosed current liabilities12,02716,3544,341
Total current liabilities:26,46221,23514,099
Noncurrent Liabilities
Long-term debt and lease obligation8911,3321,683
Operating lease, liability8911,3321,683
Other undisclosed noncurrent liabilities(891)(1,332) 
Total noncurrent liabilities:8911,3321,683
Total liabilities:27,35322,56715,782
Stockholders' equity
Stockholders' equity attributable to parent62,53981,93932,607
Common stock321
Additional paid in capital328,958242,78099,378
Accumulated other comprehensive loss(107)(112)(2)
Accumulated deficit(266,315)(160,731)(66,770)
Total stockholders' equity:62,53981,93932,607
TOTAL LIABILITIES AND EQUITY:89,892104,50648,389

Income statement (P&L) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
Operating expenses(105,618)(94,466)(45,582)
Operating loss:(105,618)(94,466)(45,582)
Nonoperating income3450569
Other nonoperating expense(521)(54)(24)
Net loss available to common stockholders, diluted:(105,584)(93,961)(45,513)

Comprehensive Income ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
Net loss:(105,584)(93,961)(45,513)
Other comprehensive income (loss)5(110)(2)
Comprehensive loss, net of tax, attributable to parent:(105,579)(94,071)(45,515)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: